BACKGROUND: Psoriasis is a common disease and the costs of its therapy, medical care and loss of productivity are a major financial burden for patients and society. The financial status of psoriasis patients and its relationship with disease severity and quality of life (QoL) remains ill characterized. OBJECTIVE: The aim of this study was to assess the economic status of psoriasis patients and to investigate its correlation with disease severity and its impact on QoL. METHODS: A total of 83 (45 male) psoriasis patients, treated at a Polish specialty clinic, were assessed for their financial and employment status. QoL was measured with a generic (WHOQOL-BREF) and a skin disease-related QoL instrument (dermatology life quality index--DLQI). The effects of demographic and clinical variables, including disease severity measured by Psoriasis Area and Severity Index (PASI), on the family income of patients were analyzed by multiple logistic regression. The mediating effect of family income between PASI and QoL was assessed by using the Baron and Kenny's procedure. RESULTS: Patients' family income correlate negatively with psoriasis severity (Spearman's rho = -0.356; P < 0.01). Disease severity in patients with a family income below the social minimum was significantly higher (PASI: 20.5 ± 12.2) than in patients with a higher family income (PASI: 11.7 ± 7.7, P < 0.001). We found that education, disease severity and age predict 50% of the variability in family income (P < 0.001). Disease severity showed the second strongest impact on income after education (P < 0.01). Family income was found to link disease severity to global QoL impairment (P < 0.05). CONCLUSION: Disease severity negatively affects the financial status of psoriasis patients, which in turn, is a mediator of global QoL impairment. Our findings are alarming and call for long-term solutions that equalize employment opportunities for patients with psoriasis.
BACKGROUND:Psoriasis is a common disease and the costs of its therapy, medical care and loss of productivity are a major financial burden for patients and society. The financial status of psoriasispatients and its relationship with disease severity and quality of life (QoL) remains ill characterized. OBJECTIVE: The aim of this study was to assess the economic status of psoriasispatients and to investigate its correlation with disease severity and its impact on QoL. METHODS: A total of 83 (45 male) psoriasispatients, treated at a Polish specialty clinic, were assessed for their financial and employment status. QoL was measured with a generic (WHOQOL-BREF) and a skin disease-related QoL instrument (dermatology life quality index--DLQI). The effects of demographic and clinical variables, including disease severity measured by Psoriasis Area and Severity Index (PASI), on the family income of patients were analyzed by multiple logistic regression. The mediating effect of family income between PASI and QoL was assessed by using the Baron and Kenny's procedure. RESULTS:Patients' family income correlate negatively with psoriasis severity (Spearman's rho = -0.356; P < 0.01). Disease severity in patients with a family income below the social minimum was significantly higher (PASI: 20.5 ± 12.2) than in patients with a higher family income (PASI: 11.7 ± 7.7, P < 0.001). We found that education, disease severity and age predict 50% of the variability in family income (P < 0.001). Disease severity showed the second strongest impact on income after education (P < 0.01). Family income was found to link disease severity to global QoL impairment (P < 0.05). CONCLUSION: Disease severity negatively affects the financial status of psoriasispatients, which in turn, is a mediator of global QoL impairment. Our findings are alarming and call for long-term solutions that equalize employment opportunities for patients with psoriasis.
Authors: Lam C Tsoi; Sarah L Spain; Eva Ellinghaus; Philip E Stuart; Francesca Capon; Jo Knight; Trilokraj Tejasvi; Hyun M Kang; Michael H Allen; Sylviane Lambert; Stefan W Stoll; Stephan Weidinger; Johann E Gudjonsson; Sulev Koks; Külli Kingo; Tonu Esko; Sayantan Das; Andres Metspalu; Michael Weichenthal; Charlotta Enerback; Gerald G Krueger; John J Voorhees; Vinod Chandran; Cheryl F Rosen; Proton Rahman; Dafna D Gladman; Andre Reis; Rajan P Nair; Andre Franke; Jonathan N W N Barker; Goncalo R Abecasis; Richard C Trembath; James T Elder Journal: Nat Commun Date: 2015-05-05 Impact factor: 14.919
Authors: Kim A Papp; Ahmed M Soliman; Nicolae Done; Christopher Carley; Esteban Lemus Wirtz; Luis Puig Journal: Dermatol Ther (Heidelb) Date: 2021-05-21
Authors: Nick Dand; Sören Mucha; Lam C Tsoi; Satveer K Mahil; Philip E Stuart; Andreas Arnold; Hansjörg Baurecht; A David Burden; Kristina Callis Duffin; Vinod Chandran; Charles J Curtis; Sayantan Das; David Ellinghaus; Eva Ellinghaus; Charlotta Enerback; Tõnu Esko; Dafna D Gladman; Christopher E M Griffiths; Johann E Gudjonsson; Per Hoffman; Georg Homuth; Ulrike Hüffmeier; Gerald G Krueger; Matthias Laudes; Sang Hyuck Lee; Wolfgang Lieb; Henry W Lim; Sabine Löhr; Ulrich Mrowietz; Martina Müller-Nurayid; Markus Nöthen; Annette Peters; Proton Rahman; André Reis; Nick J Reynolds; Elke Rodriguez; Carsten O Schmidt; Sarah L Spain; Konstantin Strauch; Trilokraj Tejasvi; John J Voorhees; Richard B Warren; Michael Weichenthal; Stephan Weidinger; Matthew Zawistowski; Rajan P Nair; Francesca Capon; Catherine H Smith; Richard C Trembath; Goncalo R Abecasis; James T Elder; Andre Franke; Michael A Simpson; Jonathan N Barker Journal: Hum Mol Genet Date: 2017-11-01 Impact factor: 6.150